P3H4

P3H4 (SC65) is an endoplasmic reticulum-resident protein that functions in collagen post-translational modification rather than in the nuclear/synaptonemal roles once attributed to it (PMID:23959653). In the ER it forms a stable complex with prolyl 3-hydroxylase 3 (P3H3), and this complex regulates the activity of lysyl hydroxylase 1 (LH1) on collagen, potentially through interactions involving LH1 and cyclophilin B (PMID:27119146). P3H4 and P3H3 act together specifically to hydroxylate lysines at helical-domain cross-linking sites in fibrillar collagens across skin, bone, tendon, aorta, and cornea, without affecting prolyl 3-hydroxylation; loss of either protein alters divalent aldimine cross-link chemistry and reverses the bone mature cross-link ratio, phenocopying EDS VIA (PLOD1 deficiency) (PMID:28115524). Consistent with this biochemical role, loss of P3H4 destabilizes the ER complex and produces collagen lysine under-hydroxylation, low bone mass, and skin fragility, with progressive osteopenia driven by non-cell-autonomous increased osteoclastogenesis (PMID:23959653, PMID:27119146). In cancer contexts, P3H4 transcription is directly activated by ETV4 in bladder cancer, where it supports proliferation, cell-cycle progression, migration, and invasion (PMID:32018225), and its mRNA stability is regulated by METTL3-mediated m6A modification (PMID:37979898).

1. 2014 Medium

   Established that SC65/P3H4 is an ER-resident protein in somatic cells rather than a nuclear synaptonemal-complex component, reassigning its cellular compartment and linking it to skeletal homeostasis.

   Evidence Subcellular fractionation and immunofluorescence plus Sc65 knockout mouse bone phenotyping (microCT, histomorphometry)

   PMID:23959653

   Open questions at the time

   • Molecular mechanism connecting ER localization to the osteoclast phenotype not defined
   • Non-cell-autonomous signal driving osteoclastogenesis not identified
2. 2016 High

   Defined the molecular partnership: SC65/P3H4 forms an ER complex with P3H3 that regulates LH1-mediated collagen lysine hydroxylation, explaining the bone and skin phenotypes.

   Evidence Co-immunoprecipitation of ER complex components, MS-based collagen modification analysis, and connective-tissue phenotyping in Sc65 knockout mice

   PMID:27119146

   Open questions at the time

   • Direct enzymatic role of P3H4 within the complex not established (non-enzymatic scaffold vs. catalytic)
   • Precise stoichiometry and contributions of LH1 and cyclophilin B unresolved
3. 2017 High

   Mapped substrate specificity to helical-domain cross-linking lysines and showed the pathway controls cross-link chemistry, demonstrating that P3H4/P3H3 loss phenocopies EDS VIA.

   Evidence Tandem MS substrate mapping and quantitative cross-link analysis on collagen from Sc65-/- and P3h3-/- mouse tissues across multiple tissue types

   PMID:28115524

   Open questions at the time

   • How the complex confers site-specificity to LH1 at helical sites is unknown
   • Whether human P3H4 mutations cause an EDS-like disorder not addressed in the corpus
4. 2020 Medium

   Identified an upstream transcriptional driver of P3H4 in cancer, showing ETV4 directly activates P3H4 to support bladder tumor cell growth and invasion.

   Evidence ChIP and promoter reporter assays, shRNA knockdown with ETV4-overexpression rescue, and xenograft tumor model in bladder cancer cells

   PMID:32018225

   Open questions at the time

   • Effector mechanism linking P3H4 to proliferation/invasion not defined
   • Relationship between cancer role and ER collagen function unclear
5. 2022 Low

   Proposed a non-collagen interaction by reporting P3H4 binding to EGFR in lung adenocarcinoma.

   Evidence Co-immunoprecipitation/interaction assay and knockdown/overexpression in LUAD cell lines with in vivo tumor models

   PMID:35805016

   Open questions at the time

   • Single Co-IP without reciprocal validation or detailed mechanistic follow-up
   • Direct vs. indirect EGFR association not established
6. 2023 Medium

   Showed post-transcriptional control of P3H4 in cancer, with METTL3-mediated m6A modification stabilizing P3H4 mRNA to promote bladder cancer phenotypes.

   Evidence mRNA half-life assays after METTL3 knockdown plus knockdown/overexpression rescue and in vivo xenograft with IHC

   PMID:37979898

   Open questions at the time

   • Specific m6A sites on P3H4 mRNA not mapped
   • Reader protein mediating stabilization not identified
7. 2025 Low

   Linked P3H4 to a signaling/metabolic output in hepatocellular carcinoma via PI3K/AKT and glycolysis.

   Evidence shRNA knockdown with viability, glycolysis (glucose/lactate/ATP), and PI3K/AKT phospho-western readouts plus nude mouse xenograft

   PMID:41220593

   Open questions at the time

   • Pathway placement inferred from phosphorylation changes without direct mechanistic link to P3H4 activity
   • Connection to ER collagen-modifying function unexplained

• How P3H4's defined ER collagen-modifying role mechanistically relates to its reported oncogenic functions, and whether human P3H4 variants cause connective-tissue disease, remains unresolved.
• No reconciliation between scaffolding role in collagen hydroxylation and cancer signaling functions
• No human genetic disease evidence in the corpus
• No structural model of the P3H4/P3H3/LH1/cyclophilin B complex